<DOC>
	<DOCNO>NCT01217125</DOCNO>
	<brief_summary>The purpose study determine whether rapamycin safe effective treatment renal angiomyolipomas patient tuberousclerosis .</brief_summary>
	<brief_title>Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiomyolipoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Diagnosis tuberousclerosis Angiomyolipoma &gt; 2cm age &gt; 10 year Creatinine &gt; 4 No recent AML bleeding No hepatic abnormality ( liver test 2fold ) Hematocrit &lt; 27 % Thrombocytopenia ( &lt; 100.000/mm3 ) Leukopenia ( &lt; 3000/mm3 ) Ischemic cardiopathy Recent surgery ( 2 month prior enrollment ) Pregnancy Serum cholesterol 7.8 mmol/l hypertriglyceridemia fasten ( &gt; 4.6 mmol/l ) non control drug malignancy previous 2 year allergy macrolides</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>tuberousclerosis , angiomyolipoma , rapamycin</keyword>
</DOC>